Ligand Ontak To Cost $25,000-$50,000 Per Year; CTLC Drug Approved Feb. 5
Executive Summary
Ligand's Ontak will cost approximately $25,000-$50,000 per patient, depending on the dose and number of cycles selected for the cutaneous T-cell lymphoma therapy.
You may also be interested in...
Targretin Is Second Product In Ligand CTCL Therapy Triple Offering
The approval of Targretin capsules is the second step in Ligand's plan to offer patients with cutaneous T-cell lymphoma treatment options for all stages of the disease. The company currently markets Ontak and recently submitted an NDA for Targretin Gel.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011